Parallax Volatility Advisers
HUMA icon

Parallax Volatility Advisers’s Humacyte HUMA Stock Holding History

Parallax Volatility Advisers’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-35,000
Closed -$112K – 3211
2022
Q2 		$112K Hold
35,000
– – ﹤0.01% 2335
2022
Q1 		$247K Buy
+35,000
New +$204K ﹤0.01% 2114

Other funds holding HUMA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
YCMGA
York Capital Management Global Advisors New York $87.8M AUM 45.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.37B AUM 23.81% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Parallax Volatility Advisers's HUMA Position: Q3 2022 in Review

Parallax Volatility Advisers sold out of Humacyte (HUMA) in Q3 2022, closing a stake of 7,500 shares — an estimated $24K sold.

Parallax Volatility Advisers first reported a position in HUMA in Q1 2022 and held it in 2 quarters. The position peaked at $24K in Q2 2022. 70 funds tracked by Wall St. Rank hold HUMA as of Q3 2022.

  • Parallax Volatility Advisers reported no remaining Humacyte position as of Q3 2022 after selling out during the quarter.
  • Parallax Volatility Advisers sold 7,500 Humacyte shares in Q3 2022, an estimated $24K.
  • Parallax Volatility Advisers first reported a position in Humacyte in Q1 2022 and held it in 2 quarters.
  • Parallax Volatility Advisers's Humacyte position peaked at $24K in Q2 2022.
  • 70 funds tracked by Wall St. Rank held Humacyte as of Q3 2022.

Based on Parallax Volatility Advisers's 13F filing for Q3 2022, filed 14 Nov 2022.